5 Small Drug Stocks to Buy as Industry Recovery Picks Up

After a sluggish first half, the drug and biotech sector has staged a recovery over the past two to three months. This rebound was supported by major drugmakers signing drug pricing agreements with the Trump administration, which eased concerns around potential tariff-related impacts and removed a key policy overhang. Renewed momentum in mergers and acquisitions (M&A) has further strengthened investor sentiment across the industry.At the same time, innovation remains a key growth driver, with high-interest ...